DSM has reported weak Q1 performance in its pharmaceutical facing businesses. However, the company said the first signs of improvement are visible. DSM attributed its 7% growth in sales to a better performance at DSM Pharmaceutical Products and slightly better prices at DSM Sinochem Pharmaceuticals.
DSM
Wednesday 9 May 2012
Pharma weak for DSM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment